TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20712132

Group type: EXPERIMENTAL
Intervention: Glycerol eardrops with 0.5% lidocaine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Glycerol eardrops with 2% lidocaine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Glycerol eardrops
Number of subjects: 105
Study: 18359433

Group type: EXPERIMENTAL
Intervention: Relaxation training (single session + daily practice tapes for one month)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study: 15997604

Group type: EXPERIMENTAL
Intervention: Enhanced primary-care depression intervention
Number of subjects: 211

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 211
Study: 12721260

Group type: EXPERIMENTAL
Intervention: CMF plus vincristine and prednisone
Number of subjects: 905

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 905
Study: 10660814

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) combined with clonidine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clonidine monotherapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) monotherapy
Number of subjects: 24
Study: 8860030

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing devices embedded in the lingual surface of the appliance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoride-releasing acrylic polymer appliances
Number of subjects: 40
Study: 1565455

Group type: EXPERIMENTAL
Intervention: Twice-daily levobunolol (0.5%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Once-daily levobunolol (0.5%)
Number of subjects: 20
Study: 2866119

Group type: EXPERIMENTAL
Intervention: Prophylactic phenoxybenzamine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31251162

Group type: EXPERIMENTAL
Intervention: CPV case simulation-based measurement and feedback
Number of subjects: 107
Study: 29358292

Group type: EXPERIMENTAL
Intervention: Oritavancin (1,200 mg intravenous single dose)
Number of subjects: 1959

Group type: COMPARATOR
Intervention: Vancomycin (twice-daily intravenous for 7 to 10 days)
Number of subjects: 1959
Study: 27342888

Group type: EXPERIMENTAL
Intervention: Real Acupuncture Group (RAG)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sham Acupuncture Group (SAG)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 78
Study: 23697261

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (15 days treatment)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (GP2, not treated)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (GP1, non-allergic)
Number of subjects: 90
Study: 20571774

Group type: EXPERIMENTAL
Intervention: ‐1997T variant
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: Haplotype 3 (‐1997T‐1663ins + 1245G)
Number of subjects: 1717
Study: 19938924

Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nonalcohol condition
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Hypermasculine men
Number of subjects: 63
Study: 17262007

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 14

Group type: COMPARATOR
Intervention: Two or more SGAs
Number of subjects: 14
Study: 15042429

Group type: EXPERIMENTAL
Intervention: AC+CC genotype of AT1
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: TT genotype of AGT
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Family history of hypertension
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Prepregnancy BMI >= 25
Number of subjects: 114
Study: 11305827

Group type: EXPERIMENTAL
Intervention: 10 mg lidocaine plus 10 microg sufentanil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 mg lidocaine plus 10 microg sufentanil plus epinephrine 50 microg
Number of subjects: 20
Study: 9029223

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (IV) 1.3 g/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral glucose (PO) 1.3 g/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Artificially sweetened placebo (Asp) in 1 liter of water
Number of subjects: 26
Study: 7705854

Group type: EXPERIMENTAL
Intervention: Trimethoprim 320 mg/sulphamethoxazole 1600 mg by mouth for 2 days (TMPSMX)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Amoxicillin 3 gm, probenicid 1 gm, and clavulanate 125 mg by mouth once (APC)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Amoxicillin 3 gm, probenicid 1 gm, and clavulanate 125 mg by mouth once with doxycycline 100 mg BID for 7 days (APC-D)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Gentamicin 240 mg IM once (GENT)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg by mouth once (CIPRO)
Number of subjects: 517

Group type: COMPARATOR
Intervention: N/A (Control group not specified)
Number of subjects: 517
Study: 3129938

Group type: EXPERIMENTAL
Intervention: Low-dose alcohol consumption (one beverage per day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Abstention from alcohol
Number of subjects: 56
Study: 29417831

Group type: EXPERIMENTAL
Intervention: Aquatic exercise (n=31), 8-week treatment protocol, 16 individual sessions, twice a week
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient-education (n=29), group sessions, once a week
Number of subjects: 60
Study: 26811126

Group type: EXPERIMENTAL
Intervention: Alcohol beverage condition
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo beverage condition
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control beverage condition
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Emotional and alcohol-related cues
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Neutral picture cues
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Repetition priming
Number of subjects: 161
Study: 25636328

Group type: EXPERIMENTAL
Intervention: Genotyping for CYP2D6 with dosing advice communicated to the treating physician
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External reference group of patients with extensive metabolizer genotype
Number of subjects: 0
Study: 23622922

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 608

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 608
Study: 20067619

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention consisting of group educational sessions lasting a total of 10 hours
Number of subjects: 932

Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 932
Study: 18360017

Group type: EXPERIMENTAL
Intervention: manidipine/delapril
Number of subjects: 158

Group type: COMPARATOR
Intervention: olmesartan/hydrochlorothiazide
Number of subjects: 158
Study: 20617907

Group type: EXPERIMENTAL
Intervention: IT‐18 thermocouples
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PT‐6 thermocouples
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IT‐21 thermocouples
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Datalogger electrothermometer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Iso‐Thermex calibrated from ‐50 degrees C to 50 degrees C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Iso‐Thermex calibrated from ‐20 degrees C to 80 degrees C
Number of subjects: 18
Study: 16232015

Group type: EXPERIMENTAL
Intervention: Ensure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 12439260

Group type: EXPERIMENTAL
Intervention: Preoperative long leg standing radiograph
Number of subjects: 94

Group type: COMPARATOR
Intervention: No preoperative long leg standing radiograph
Number of subjects: 94
Study: 9673299

Group type: EXPERIMENTAL
Intervention: 30 microg of OspA vaccine
Number of subjects: 10305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10305
Study: 8022625

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.075%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.125%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.25%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.5%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 10
Study: 2730823

Group type: EXPERIMENTAL
Intervention: 1% lignocaine with 1 in 100,000 noradrenaline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 12048416

Group type: EXPERIMENTAL
Intervention: Deep acupuncture (needle placed deeply into muscular tissue)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Superficial acupuncture (needle introduced in the skin at a depth of 2 mm)
Number of subjects: 42
Study: 30646164

Group type: EXPERIMENTAL
Intervention: Live birth of an infant with a major congenital anomaly
Number of subjects: 42943

Group type: COMPARATOR
Intervention: Control group (comparison cohort of randomly selected women)
Number of subjects: 42943

Group type: EXPERIMENTAL
Intervention: Live birth of an infant with multiorgan anomalies
Number of subjects: 42943
Study: 26952376

Group type: EXPERIMENTAL
Intervention: Weighted exercise group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-weighted exercise group
Number of subjects: 60
Study: 23918037

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every other week (Q2W), reduced to 200 mg Q2W after ≥6 months + Methotrexate (MTX)
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) + Methotrexate (MTX)
Number of subjects: 958
Study: 22454006

Group type: EXPERIMENTAL
Intervention: Flexible extended regimen with MIB (minimum 24, maximum 120 days of continuous tablet intake)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Flexible extended regimen with MIB
Number of subjects: 223

Group type: COMPARATOR
Intervention: Conventional 28-day regimen (24 active and four placebo tablets for five cycles)
Number of subjects: 223
Study: 20149571

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Change Plan completion
Number of subjects: 291
Study: 18565425

Group type: EXPERIMENTAL
Intervention: High-selenium yeast supplementation (300 microg/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo yeast
Number of subjects: 42
Study: 16280942

Group type: EXPERIMENTAL
Intervention: Bevel-up technique
Number of subjects: 396

Group type: COMPARATOR
Intervention: Bevel-down technique
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Bevel-up technique (infants < 5 kg)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Bevel-down technique (infants < 5 kg)
Number of subjects: 396
Study: 12866946

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg test formulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atenolol 50 mg reference formulation
Number of subjects: 24
Study: 10485679

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 461

Group type: COMPARATOR
Intervention: Control
Number of subjects: 461
Study: 7851582

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate combined with hMG and FSH for ovarian stimulation
Number of subjects: 26
Study: 1828570

Group type: EXPERIMENTAL
Intervention: Calcium entry blockers (CEB)
Number of subjects: 0
Study: 7386839

Group type: EXPERIMENTAL
Intervention: Ketamine anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxant anaesthesia
Number of subjects: 0
Study: 30845995

Group type: EXPERIMENTAL
Intervention: Totally laparoscopic distal gastrectomy (TLDG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 0
Study: 30585459

Group type: EXPERIMENTAL
Intervention: EA C group (3 times: one day, 30 min before and one day after surgery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous anesthesia group
Number of subjects: 80
Study: 27716303

Group type: EXPERIMENTAL
Intervention: Realist trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 24439636

Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy (10% concentration inhaled for 5 minutes during 3 hemodialysis sessions)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (aromatherapy free of lavender essence)
Number of subjects: 92
Study: 22936194

Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg/h plus Ketamine 5 µg/kg/min and Remifentanil 0.1 µg/kg/min (GK)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Propofol 1 mg/kg/h plus Remifentanil 0.25 µg/kg/min (GR)
Number of subjects: 322
Study: 19834700

Group type: EXPERIMENTAL
Intervention: 100 mL of 300 mgI/mL
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 80 mL of 370 mgI/mL
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 60 mL of 370 mgI/mL followed by a 30‐mL saline flush
Number of subjects: 31
Study: 17393343

Group type: EXPERIMENTAL
Intervention: Int3 (intensified antidiabetic therapy for 3 weeks)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Int52 (intensified antidiabetic therapy for 52 weeks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Con3 (unchanged therapy for 3 weeks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Con52 (unchanged therapy for 52 weeks)
Number of subjects: 83
Study: 16235477

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% lignocaine with 0.5% bupivacaine
Number of subjects: 0
Study: 11872998

Group type: EXPERIMENTAL
Intervention: Concentration-controlled therapy (zidovudine, lamivudine, and indinavir)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy (zidovudine, lamivudine, and indinavir)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both concentration-controlled and conventional therapy
Number of subjects: 40
Study: 11686538

Group type: EXPERIMENTAL
Intervention: Thyroid autoantibodies (TPOAb)
Number of subjects: 2249

Group type: EXPERIMENTAL
Intervention: Islet cell autoantibodies (ICA)
Number of subjects: 2249

Group type: EXPERIMENTAL
Intervention: High ICA titers (> or = 20 JDF-U)
Number of subjects: 2249

Group type: COMPARATOR
Intervention: Low ICA titers (5-19 JDF-U)
Number of subjects: 2249

Group type: COMPARATOR
Intervention: ICA-negative sera
Number of subjects: 2249

Group type: EXPERIMENTAL
Intervention: Diabetic women (all ICA-negative)
Number of subjects: 2249
Study: 9607949

Group type: EXPERIMENTAL
Intervention: Novel biphasic delivery system
Number of subjects: 9

Group type: COMPARATOR
Intervention: Liposomal delivery system
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nonliposomal (oil/water cream) delivery system
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 9
Study: 8284002

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg at night)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 2661222

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normotensives
Number of subjects: 25
Study: 781887

Group type: EXPERIMENTAL
Intervention: Prednisone, azathioprine, and ATG
Number of subjects: 250

Group type: COMPARATOR
Intervention: Prednisone and azathioprine only
Number of subjects: 250
Study: 30734476

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cervical nerve root block (CRB) with mixed drug liquid
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (similar looking)
Number of subjects: 140
Study: 29045212

Group type: EXPERIMENTAL
Intervention: 5-mg tofacitinib
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: 10-mg tofacitinib
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 522

Group type: COMPARATOR
Intervention: placebo (switched to 5-mg tofacitinib at 3 months)
Number of subjects: 522

Group type: COMPARATOR
Intervention: placebo (switched to 10-mg tofacitinib at 3 months)
Number of subjects: 522
Study: 26899137

Group type: EXPERIMENTAL
Intervention: Mini‐laparoscopic Cholecystectomy
Number of subjects: 114

Group type: COMPARATOR
Intervention: 5mm Laparoscopic Cholecystectomy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Mini‐laparoscopic Cholecystectomy and 5mm Laparoscopic Cholecystectomy
Number of subjects: 114
Study: 22642854

Group type: EXPERIMENTAL
Intervention: Integrated care delivery
Number of subjects: 45
Study: 21816921

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI) in patients with iNPH
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Corticospinal tract (CST) tractographic images in patients with iNPH
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CST FA values in patients with iNPH
Number of subjects: 59
Study: 18952164

Group type: EXPERIMENTAL
Intervention: 1000 mg/day vitamin C
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin E
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study: 16952814

Group type: EXPERIMENTAL
Intervention: 4 mg of morphine in 10 mL of saline
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10 mL of saline
Number of subjects: 40
Study: 15265057

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (maximum 100 units)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study: 11775653

Group type: EXPERIMENTAL
Intervention: Essaven gel (EG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9322512

Group type: EXPERIMENTAL
Intervention: Fructose-glucose (FruGlu) solution
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fructose-glucose-acarbose (FruGluA) solution
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sucrose solution
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Lactulose absorption from glucose or sucrose solutions
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fructose-mannitol (FruMann) solution
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sucrose, FruGlu, and glucose solutions
Number of subjects: 7
Study: 8373602

Group type: COMPARATOR
Intervention: Midazolam (MZ) 0.02 mg/kg i.v., repeated every 2 to 3 minutes; maintenance MZ 0.005 mg/kg i.v. as necessary
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol bolus (PB) 0.75 to 1.0 mg/kg i.v.; maintenance 0.25 mg/kg i.v. as necessary
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol infusion (PI) 2 to 4 mg/kg/hr or 33 to 66 micrograms/kg/min to maintain SL3
Number of subjects: 90
Study: 3539031

Group type: EXPERIMENTAL
Intervention: Nebulised beclomethasone dipropionate suspension
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30171484

Group type: EXPERIMENTAL
Intervention: Mannitol (12 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline infusion (control)
Number of subjects: 0
Study: 27494414

Group type: EXPERIMENTAL
Intervention: 8 hours time in bed (8h TIB)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 6 hours time in bed (6h TIB)
Number of subjects: 58
Study: 25523303

Group type: EXPERIMENTAL
Intervention: Negative mood induction group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Positive mood induction group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 25234606

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) administered in 15 30-minute treatments over three weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham condition administered in 15 30-minute treatments over three weeks
Number of subjects: 0
Study: 21640535

Group type: EXPERIMENTAL
Intervention: 10% contrast medium (CM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20% contrast medium (CM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30% contrast medium (CM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 40% contrast medium (CM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: All groups except 10% CM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups (10%, 20%, 30%, 40%)
Number of subjects: 40
Study: 20840526

Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 756

Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 756
Study: 18269775

Group type: EXPERIMENTAL
Intervention: Capecitabine 1250 mg/m2 twice daily for 14 days followed by 7 days of rest
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Capecitabine 1000 mg/m2 twice daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Toxicity profile of capecitabine
Number of subjects: 37
Study: 15691667

Group type: EXPERIMENTAL
Intervention: Technetium 99m stannous colloid (99mTc SnC) uptake in neutrophils
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Technetium 99m stannous colloid (99mTc SnC) uptake in monocytes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Blood from normal individuals incubated with lysed B. pseudomallei and colloid
Number of subjects: 10
Study: 14662904

Group type: EXPERIMENTAL
Intervention: RTS,S vaccine
Number of subjects: 20
Study: 10595949

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐sestamibi injection (20 to 30 mCi) before primary angioplasty
Number of subjects: 61
Study: 8730912

Group type: EXPERIMENTAL
Intervention: Intensive one-on-one education about anxiety and periodic feedback about patients with anxiety (Intervention)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Intensive one-on-one education about anxiety (Intervention)
Number of subjects: 637
Study: 1878612

Group type: EXPERIMENTAL
Intervention: Videotaped behavioral treatment program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Videotaped placebo program
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 0
Study: 6682026

Group type: EXPERIMENTAL
Intervention: Naloxone infusion at a rate of 20 micrograms kg‐1 hr‐1
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no naloxone)
Number of subjects: 14
Study: 3887976

Group type: EXPERIMENTAL
Intervention: Oral tiaramide 200 mg four times daily
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral salbutamol 4 mg four times daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral tiaramide
Number of subjects: 35